search
Back to results

The Leadless AV Versus DDD Pacing Study (LEAVE DDD)

Primary Purpose

Cardiac Pacemaker, Arrhythmias, Cardiac, Heart Diseases

Status
Recruiting
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Conventional pacemaker DDD
Leadless pacemaker Micra AV
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiac Pacemaker focused on measuring Leadless pacemaker, Atrioventricular conduction block, Bradyarrhythmias, Micra

Eligibility Criteria

70 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients (≥70y) undergoing a de-novo pacemaker implantation due to intermittent or permanent AV block, qualifying for a conventional or leadless pacemaker
  • Written informed consent

Exclusion Criteria:

  • Permanent atrial fibrillation or atrial standstill
  • Evidence of sinus node disease and need for right atrial pacing (not possible with Micra AV)
  • LVEF <50% and permanent high-degree or total AVB (requiring CRT/His-Bundle/CSP pacing)
  • Preoperative E/A ratio >1.5 in the echocardiography
  • Any co-existing ICD indications (no leadless ICD systems available)
  • Hemodialysis
  • Presence of a mechanical tricuspid valve prosthesis
  • Unwilling or unable to comply fully with study procedures and follow-up

Sites / Locations

  • Inselspital, Bern University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Conventional pacemaker DDD

Leadless pacemaker Micra AV

Arm Description

Implantation of a conventional dual-chamber PM

Implantation of a leadless pacemaker system (Micra AV™)

Outcomes

Primary Outcome Measures

Exercise capacity
Exercise capacity (VO2 at anaerobic threshold) as assessed by spiroergometry

Secondary Outcome Measures

Total implantation time
Total implantation time
Total fluoroscopy time
Total fluoroscopy time during implantation
Total fluoroscopy dosage
Total fluoroscopy dosage during implantation
Pacing thresholds
Pacing thresholds of the implanted pacemaker
Sensing values
Sensing values of the implanted pacemaker
Impedance values
Impedance values of the implanted pacemaker
Duration of exercise
Duration of exercise until exhaustion assessed by spiroergometry
VO2max
VO2max assessed by spiroergometry
VE/VCO2
VE/VCO2 assessed by spiroergometry
VE/VO2
VE/VO2 assessed by spiroergometry
Maximum atrial heart rate
Maximum atrial heart rate as assessed by spiroergometry
Left ventricular ejection fraction (LVEF)
LVEF as assessed by echocardiography
Degree of tricuspid valve regurgitation
Degree of tricuspid valve regurgitation assessed by trans-thoracic echocardiogram. The degree of tricuspid valve regurgitation will be classified as "none", "mild", "moderate" or "severe"
Degree of mitral valve regurgitation
Degree of mitral valve regurgitation assessed by trans-thoracic echocardiogram. The degree of mitral valve regurgitation will be classified as "none", "mild", "moderate" or "severe"
Quality of Life scores measured with the EQ-5D-5L Questionnaire
Quality of Life scores measured with the EQ-5D-5L Questionnaire Scores: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with a 5-scale response option; current health state assessed with a number between 0 and 100
AV synchrony
Laboratory
NT-proBNP
Safety outcomes
Major adverse events (death, cardiac tamponade, any surgical reintervention, pocket/groin problems, lead/device dislocations; electrode noise, pacing impedance out of range (<200 or >2000Ω), failure to capture at maximum output, infections and thrombosis/embolism); rate of pacemaker syndrome developed by patients; rate of device upgrades/revisions required

Full Information

First Posted
August 3, 2022
Last Updated
September 6, 2022
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
University of Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT05498376
Brief Title
The Leadless AV Versus DDD Pacing Study
Acronym
LEAVE DDD
Official Title
The Leadless AV Versus DDD Pacing Study: A Randomized Controlled Single-center Trial on Leadless Versus Conventional Cardiac Dual-chamber Pacing
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 23, 2022 (Actual)
Primary Completion Date
May 31, 2024 (Anticipated)
Study Completion Date
February 28, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
University of Bern

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Cardiac pacemaker (PM) implantation is the established treatment for relevant bradyarrhythmias. Conventional PMs require 1-3 pacing leads to register the heart's intrinsic activity ("sensing") and to deliver the electrical stimuli to the heart ("pacing"). These leads are responsible for the vast majority of morbidity after implantation and PM failures. Therefore, a leadless PM system (Micra TPS™, Medtronic, United States) has been introduced a few years ago. This system overcomes the limitations of leads, however, the first generation of the Micra TPS™ only allowed sensing and pacing in the right ventricle. More recently, an upgraded version has been introduced and gained market approval (Micra AV, Medtronic, United States). According to published results from several clinical trials, this device allows sensing the atrial activity and, thus, timing the delivery of the ventricular pacing impulse in a physiological manner similar to a conventional dual-chamber PM with two leads. Clinical feasibility and safety for this concept have been established already. However, it is unclear if this translates into a direct clinical benefit for patients in comparison to conventional PM systems. The aim of this trial is to compare the therapeutic efficacy of the Micra AV™ PM and conventional dual-chamber PM systems in patients with intermittent or permanent atrioventricular conduction block and a PM indication according to the latest European guidelines. Thus, patients will be randomized to either a conventional dual-chamber PM implantation or the implantation of a leadless Micra AV™ system. Patients will be stratified for gender (female/male) and a priori estimated physical exercise capacity ("fit"/"unfit"). The primary outcome will be the physical exercise capacity of the patients. The null hypothesis with regards to the primary endpoint is that the leadless pacemaker arm shows an inferior VO2 anaerobic threshold than the conventional pacemaker arm. Hence the alternative hypothesis postulates that the leadless pacemaker arm shows a non-inferior VO2 anaerobic threshold compared to the conventional pacemaker arm. Rejection of the null hypothesis is needed to conclude non-inferiority.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Pacemaker, Arrhythmias, Cardiac, Heart Diseases, Cardiovascular Diseases
Keywords
Leadless pacemaker, Atrioventricular conduction block, Bradyarrhythmias, Micra

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Conventional pacemaker DDD
Arm Type
Active Comparator
Arm Description
Implantation of a conventional dual-chamber PM
Arm Title
Leadless pacemaker Micra AV
Arm Type
Active Comparator
Arm Description
Implantation of a leadless pacemaker system (Micra AV™)
Intervention Type
Device
Intervention Name(s)
Conventional pacemaker DDD
Intervention Description
Implantation of a conventional cardiac pacemaker
Intervention Type
Device
Intervention Name(s)
Leadless pacemaker Micra AV
Intervention Description
Implantation of a leadless cardiac pacemaker
Primary Outcome Measure Information:
Title
Exercise capacity
Description
Exercise capacity (VO2 at anaerobic threshold) as assessed by spiroergometry
Time Frame
Month 3 post implantation
Secondary Outcome Measure Information:
Title
Total implantation time
Description
Total implantation time
Time Frame
During implantation on day 0
Title
Total fluoroscopy time
Description
Total fluoroscopy time during implantation
Time Frame
During implantation on day 0
Title
Total fluoroscopy dosage
Description
Total fluoroscopy dosage during implantation
Time Frame
During implantation on day 0
Title
Pacing thresholds
Description
Pacing thresholds of the implanted pacemaker
Time Frame
Days 0,1 and months 1,3,12 and 24 post implantation
Title
Sensing values
Description
Sensing values of the implanted pacemaker
Time Frame
Days 0,1 and months 1,3,12 and 24 post implantation
Title
Impedance values
Description
Impedance values of the implanted pacemaker
Time Frame
Days 0,1 and months 1,3,12 and 24 post implantation
Title
Duration of exercise
Description
Duration of exercise until exhaustion assessed by spiroergometry
Time Frame
Month 3 post implantation
Title
VO2max
Description
VO2max assessed by spiroergometry
Time Frame
Month 3 post implantation
Title
VE/VCO2
Description
VE/VCO2 assessed by spiroergometry
Time Frame
Month 3 post implantation
Title
VE/VO2
Description
VE/VO2 assessed by spiroergometry
Time Frame
Month 3 post implantation
Title
Maximum atrial heart rate
Description
Maximum atrial heart rate as assessed by spiroergometry
Time Frame
Month 3 post implantation
Title
Left ventricular ejection fraction (LVEF)
Description
LVEF as assessed by echocardiography
Time Frame
Day 0 and months 3, 12 and 24 post implantation
Title
Degree of tricuspid valve regurgitation
Description
Degree of tricuspid valve regurgitation assessed by trans-thoracic echocardiogram. The degree of tricuspid valve regurgitation will be classified as "none", "mild", "moderate" or "severe"
Time Frame
Day 0 and months 3, 12 and 24 post implantation
Title
Degree of mitral valve regurgitation
Description
Degree of mitral valve regurgitation assessed by trans-thoracic echocardiogram. The degree of mitral valve regurgitation will be classified as "none", "mild", "moderate" or "severe"
Time Frame
Day 0 and months 3, 12 and 24 post implantation
Title
Quality of Life scores measured with the EQ-5D-5L Questionnaire
Description
Quality of Life scores measured with the EQ-5D-5L Questionnaire Scores: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, each with a 5-scale response option; current health state assessed with a number between 0 and 100
Time Frame
Days 0,1 and months 1,3,12 and 24 post implantation
Title
AV synchrony
Time Frame
Day 1 and months 1,3,12 and 24 post implantation
Title
Laboratory
Description
NT-proBNP
Time Frame
Day 0 and month 3 post implantation
Title
Safety outcomes
Description
Major adverse events (death, cardiac tamponade, any surgical reintervention, pocket/groin problems, lead/device dislocations; electrode noise, pacing impedance out of range (<200 or >2000Ω), failure to capture at maximum output, infections and thrombosis/embolism); rate of pacemaker syndrome developed by patients; rate of device upgrades/revisions required
Time Frame
Days 0,1 and months 1,3,12 and 24 post implantation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients (≥70y) undergoing a de-novo pacemaker implantation due to intermittent or permanent AV block, qualifying for a conventional or leadless pacemaker Written informed consent Exclusion Criteria: Permanent atrial fibrillation or atrial standstill Evidence of sinus node disease and need for right atrial pacing (not possible with Micra AV) LVEF <50% and permanent high-degree or total AVB (requiring CRT/His-Bundle/CSP pacing) Preoperative E/A ratio >1.5 in the echocardiography Any co-existing ICD indications (no leadless ICD systems available) Hemodialysis Presence of a mechanical tricuspid valve prosthesis Unwilling or unable to comply fully with study procedures and follow-up
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andreas Häberlin, MD
Phone
+41 31 664 06 74
Email
Andreas.Haeberlin@insel.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas Häberlin, MD
Organizational Affiliation
Inselspital, Bern University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Inselspital, Bern University Hospital
City
Bern
ZIP/Postal Code
3010
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Häberlin, MD
Phone
+41 31 664 06 74
Email
Andreas.Haeberlin@insel.ch

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

The Leadless AV Versus DDD Pacing Study

We'll reach out to this number within 24 hrs